SG10201912150TA - Anti-trem2 antibodies and methods of use thereof - Google Patents

Anti-trem2 antibodies and methods of use thereof

Info

Publication number
SG10201912150TA
SG10201912150TA SG10201912150TA SG10201912150TA SG10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA SG 10201912150T A SG10201912150T A SG 10201912150TA
Authority
SG
Singapore
Prior art keywords
methods
trem2 antibodies
trem2
antibodies
Prior art date
Application number
SG10201912150TA
Other languages
English (en)
Inventor
Tina Schwabe
Francesca Avogadri-Connors
Helen Lam
Ilaria Tassi
Seung-Joo Lee
Arnon Rosenthal
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of SG10201912150TA publication Critical patent/SG10201912150TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201912150TA 2015-10-06 2016-10-06 Anti-trem2 antibodies and methods of use thereof SG10201912150TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562238044P 2015-10-06 2015-10-06
US201662369666P 2016-08-01 2016-08-01

Publications (1)

Publication Number Publication Date
SG10201912150TA true SG10201912150TA (en) 2020-02-27

Family

ID=57178515

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201912150TA SG10201912150TA (en) 2015-10-06 2016-10-06 Anti-trem2 antibodies and methods of use thereof

Country Status (9)

Country Link
US (2) US20190330335A1 (ja)
EP (1) EP3359569A2 (ja)
JP (2) JP2018537956A (ja)
KR (1) KR20180068999A (ja)
CN (2) CN108738323B (ja)
AU (2) AU2016334051B2 (ja)
CA (1) CA2997960A1 (ja)
SG (1) SG10201912150TA (ja)
WO (1) WO2017062672A2 (ja)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SG10201913611QA (en) 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
IL283834B (en) 2014-09-28 2022-07-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3022765A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
WO2018015573A2 (en) * 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
WO2018191548A2 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
KR20200030029A (ko) 2017-05-02 2020-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
AU2018289428A1 (en) * 2017-06-21 2020-02-06 The General Hospital Corporation Methods and compositions for chimeric antigen receptor targeting cancer cells
WO2019018828A1 (en) * 2017-07-20 2019-01-24 Cytomx Therapeutics, Inc. METHODS OF QUALITATIVE AND / OR QUANTITATIVE ANALYSIS OF ACTIVATABLE ANTIBODY PROPERTIES AND USES THEREOF
TWI811229B (zh) 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
CN111448212A (zh) * 2017-09-14 2020-07-24 戴纳立制药公司 抗trem2抗体及其使用方法
CA3077247A1 (en) * 2017-10-16 2019-04-25 Eisai R & D Management Co., Ltd. Anti-tau antibodies and uses thereof
AU2018383709A1 (en) 2017-12-12 2020-07-16 Pionyr Immunotherapeutics, Inc. Anti-TREM2 antibodies and related methods
WO2019222104A1 (en) * 2018-05-18 2019-11-21 Macrogenics, Inc. Optimized gp41-binding molecules and uses thereof
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
AU2019339452A1 (en) * 2018-09-11 2021-03-25 Washington University Anti-trem-2 agonist antibodies
JP2022512591A (ja) * 2018-10-05 2022-02-07 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 原発性免疫不全症、シスチン症、及びウィルソン病に関する新生児スクリーニング
UY38407A (es) * 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
JP2022512629A (ja) * 2018-10-23 2022-02-07 マジェンタ セラピューティクス インコーポレイテッド Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
KR102156165B1 (ko) * 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
WO2020121195A1 (en) * 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
CN113194994A (zh) * 2018-12-11 2021-07-30 开拓免疫医疗公司 使用抗trem2抗体的方法
US20220275067A1 (en) * 2019-02-08 2022-09-01 Prothena Biosciences Limited Antibodies recognizing tau
JP2022520868A (ja) * 2019-02-20 2022-04-01 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
EP3931349A4 (en) * 2019-02-28 2023-02-08 The Rockefeller University APOE GENOTYPING IN CANCER PROGNOSTIC AND TREATMENT
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN110320368A (zh) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3159055A1 (en) * 2019-11-22 2021-05-27 Forest Hoyt ANDREWS Trem2 antibodies and uses thereof
MX2022006073A (es) 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
TW202128771A (zh) * 2020-01-13 2021-08-01 美商戴納立製藥公司 抗trem2 抗體及其使用方法
CN115279790A (zh) 2020-01-13 2022-11-01 戴纳立制药公司 抗trem2抗体和其使用方法
CA3167851A1 (en) 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
US11940448B2 (en) 2020-03-31 2024-03-26 Seattle Children's Hospital Proteomic screening for lysosomal storage diseases
CN115667308A (zh) 2020-04-03 2023-01-31 艾利妥 抗trem2抗体的使用方法
JP2023522730A (ja) * 2020-04-22 2023-05-31 アケソ・バイオファーマ・インコーポレイテッド 抗ｃｄ７３／抗ｐｄ－１二重特異性抗体及びその使用
CA3181207A1 (en) * 2020-06-26 2021-12-30 Bioarctic Ab A-synuclein protofibril-binding antibodies
CN111944050B (zh) * 2020-08-19 2022-05-13 苏州普乐康医药科技有限公司 一种抗b7-h3抗体及其应用
JP2023551542A (ja) 2020-11-30 2023-12-08 エニグマ バイオインテリジェンス，インコーポレイテッド アルツハイマー病の非侵襲的評価
AU2021392813A1 (en) * 2020-12-04 2023-06-29 Vigil Neuroscience, Inc. Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
AU2022209701A1 (en) * 2021-01-21 2023-08-31 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
CN112979795B (zh) * 2021-02-26 2022-07-08 深圳市亚辉龙生物科技股份有限公司 抗体组合产品及其在新冠肺炎检测中应用
US11904020B2 (en) * 2021-03-19 2024-02-20 Bicycletx Limited Bicyclic peptide ligands specific for TREM2
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
WO2022245553A2 (en) * 2021-05-19 2022-11-24 Signablk, Inc. Trem-2/dap-12 inhibitors for treating lung disease and injury and combinations thereof
WO2023022729A1 (en) * 2021-08-20 2023-02-23 Tasrif Pharmaceutical, LLC Antibodies and antigen binding fragments against cd155 methods of use thereof
WO2023039450A2 (en) * 2021-09-07 2023-03-16 Duke University Compositions and methods for treatment of retinal degeneration
TW202340235A (zh) 2021-12-17 2023-10-16 美商戴納立製藥公司 多肽工程、文庫及工程ｃｄ９８重鏈以及轉鐵蛋白受體結合多肽
WO2023137466A2 (en) * 2022-01-14 2023-07-20 Qilu Puget Sound Biotherapeutics Corporation Anti-ccr8 antibodies
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2023212707A2 (en) * 2022-04-29 2023-11-02 The Children's Medical Center Corporation Therapeutic modulation of genes in myeloid lineage cells and uses thereof in ophthalmology
WO2024052343A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
PT1034298E (pt) 1997-12-05 2012-02-03 Scripps Research Inst Humanização de anticorpo murino
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
JP2004073182A (ja) * 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
AU2003301882A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
AU2003303384A1 (en) * 2002-12-23 2004-07-22 Schering Corporation Uses of mammalian cytokine; related reagents
EA200701211A1 (ru) 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
KR20140057635A (ko) 2006-03-15 2014-05-13 알렉시온 파마슈티칼스, 인코포레이티드 보체의 저해물질로 발작성 야간혈색뇨증 환자의 치료
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
EP2195344A4 (en) * 2007-10-05 2011-07-06 Univ Maryland NOVEL COMPOSITIONS AND METHODS FOR STIMULATING ERYTHROPOISIS IN MAMMALS
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US10584181B2 (en) * 2009-12-04 2020-03-10 Genentech, Inc. Methods of making and using multispecific antibody panels and antibody analog panels
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
SG10201913611QA (en) * 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof

Also Published As

Publication number Publication date
CA2997960A1 (en) 2017-04-13
US20190330335A1 (en) 2019-10-31
EP3359569A2 (en) 2018-08-15
AU2024200443A1 (en) 2024-04-04
JP2023093528A (ja) 2023-07-04
CN108738323B (zh) 2023-05-26
WO2017062672A3 (en) 2017-05-26
US20230295297A1 (en) 2023-09-21
JP2018537956A (ja) 2018-12-27
WO2017062672A2 (en) 2017-04-13
KR20180068999A (ko) 2018-06-22
AU2016334051B2 (en) 2023-10-26
CN117069841A (zh) 2023-11-17
AU2016334051A1 (en) 2018-04-12
CN108738323A (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1249445A1 (zh) 抗分揀蛋白抗體和其使用方法
IL259495A (en) Antibodies and methods for using them
HK1252698A1 (zh) 抗siglec-9抗體及其使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
HK1252696A1 (zh) 抗siglec-7抗體及其使用方法
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
HK1258850A1 (zh) 抗tpbg抗體及使用方法